The review, published in the Current Neuroscience Journal by Priyanka Yadav, Dinesh Kumar, Anil Kumar, and corresponding author Sumit Kumar, maps the molecular chain of events through which oxidative stress drives the destruction of nerve cells. Drawing together evidence across five major neurological conditions — Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and epilepsy — the authors make a case that is both sobering and constructive: oxidative stress is not a single entity that can be neutralised with a single pill, but a family of disease-specific chemical processes that demand precision-targeted interventions.

At modest levels, reactive oxygen species are not merely harmless; they are essential. They participate in nerve cell signalling, help sculpt the synaptic connections that underlie learning and memory, and support immune responses within brain tissue. The trouble begins when production outpaces the brain’s capacity for neutralisation, a state scientists call oxidative stress. Because neurons are rich in the polyunsaturated fatty acids that reactive molecules attack most readily, and because the brain maintains comparatively weak antioxidant defences relative to other organs, it is uniquely vulnerable to this kind of chemical damage. Once stress becomes sustained, the consequences cascade: fatty cell membranes are peroxidised, proteins are corrupted and lose their function, DNA strands accumulate lesions, mitochondrial energy machinery falters, chronic inflammation takes hold in brain tissue, and misfolded proteins begin to aggregate into the abnormal clumps that define several neurodegenerative diseases.

What makes the review particularly valuable is its insistence on mechanistic specificity. All five diseases share a common foundation — failing mitochondria, weakened antioxidant defences, excitotoxic excess at synapses, chronic low-grade neuroinflammation, and the accumulation of proteins the cell cannot clear. But the specific chemical routes by which oxidative stress inflicts damage diverge dramatically, and those differences have profound implications for therapy.

Consider Parkinson’s disease, a condition defined by the death of dopamine-producing neurons. Dopamine itself is a chemically restless molecule. Its normal metabolic breakdown generates reactive quinones — dopamine quinones — that are directly toxic to the very neurons that manufacture the neurotransmitter. The result is a self-reinforcing cycle of destruction: the more dopamine is metabolised, the more toxic byproducts accumulate, and the fewer healthy neurons remain to handle the load. Any antioxidant strategy for Parkinson’s that ignores this dopamine-specific chemistry is, the authors suggest, unlikely to succeed.

In amyotrophic lateral sclerosis, the story unfolds differently. Mutations in the SOD1 gene, which encodes one of the cell’s most important antioxidant enzymes, produce a misfolded protein that is not merely inactive but actively poisonous. This corrupted enzyme disrupts redox balance with particular specificity in motor neurons — the large, metabolically demanding cells that control voluntary movement — helping explain why ALS devastates movement while leaving cognition and sensation comparatively intact for much of the disease course.

Alzheimer’s disease presents yet another mechanism. The amyloid-beta fragments that accumulate into the disease’s characteristic plaques act as catalysts for redox-active metal ions such as copper and iron. In the presence of these metals, amyloid-beta drives the generation of highly reactive hydroxyl radicals, producing sharply localised oxidative damage in the immediate vicinity of plaques. Oxidative stress in Alzheimer’s is thus not a diffuse background phenomenon but a concentrated chemical assault, orchestrated in part by the very protein aggregates considered hallmarks of the disease.

Huntington’s disease adds a fourth variant. The mutant huntingtin protein physically impairs mitochondrial function, choking off energy supply and simultaneously increasing the generation of oxidative byproducts. This double blow falls hardest on the striatum, the brain region most affected by the disease, providing a mechanistic explanation for the movement disorders and cognitive decline that characterise the condition. Epilepsy, meanwhile, illustrates how oxidative stress and excitotoxicity feed each other: excessive neuronal firing generates reactive species, which in turn damage the cellular machinery that normally restrains excitability.

The review also devotes careful attention to how oxidative damage is actually measured, an issue of more than academic interest. Researchers rely on a panel of biomarkers: F2-isoprostanes and malondialdehyde as indicators of lipid peroxidation, protein carbonyls and 3-nitrotyrosine as markers of protein oxidation, and 8-hydroxy-2′-deoxyguanosine as evidence of DNA damage. Crucially, the authors draw a conceptual distinction between oxidative stress — the imbalance between production and defence — and oxidative damage, the measurable molecular harm that results. A cell can be under significant stress without yet showing damage if its defences are compensating, and a treatment that reduces one without addressing the other may produce encouraging biomarker readings while failing to change the disease’s trajectory.

This distinction feeds directly into the review’s most provocative argument: an explanation for why antioxidant therapies have so consistently disappointed in clinical trials. Despite decades of compelling laboratory evidence linking oxidative stress to neurodegeneration, broad-spectrum antioxidants have repeatedly failed to deliver meaningful benefits to patients. The authors identify several reasons. Antioxidant drugs must cross the blood-brain barrier in sufficient concentrations, a formidable pharmacological obstacle. Many act at the wrong point in the damage cascade or against the wrong reactive species. Preclinical disease models frequently fail to capture the complexity and chronicity of human neurodegeneration, producing results that simply do not translate.

But the deepest problem may be conceptual. Reactive oxygen species are not waste products to be eliminated; they are signalling molecules woven into the normal fabric of brain function. Indiscriminately suppressing their production risks disrupting the very cellular processes a therapy is meant to protect. A blunt chemical hammer, in other words, cannot fix a system that depends on precisely calibrated chemistry.

The path forward, the authors argue, requires abandoning the shotgun approach. Future therapies should target the specific oxidative pathways relevant to each disease — dopamine quinones in Parkinson’s, SOD1 misfolding in ALS, metal-catalysed oxidation in Alzheimer’s, mitochondrial impairment in Huntington’s — and must be deployed at the appropriate stage of disease progression and within the appropriate cellular compartment. Timing matters as much as target: intervening after decades of accumulated damage may be futile even with the right molecule. Equally important is the smarter use of oxidative damage biomarkers in clinical trials, both to identify the patients most likely to benefit from antioxidant interventions and to verify that a treatment is genuinely reducing oxidative stress in the brain rather than merely performing well on surrogate measures.

For the tens of millions of people worldwide living with these five conditions, and for whom disease-modifying treatments remain painfully elusive, the review offers neither a cure nor a quick breakthrough. What it offers instead is something arguably more valuable at this stage: a coherent mechanistic framework that explains past failures and charts a disciplined route toward therapies that treat oxidative stress not as a generic enemy to be eradicated, but as a set of distinct, disease-specific vulnerabilities to be precisely addressed. In the difficult terrain of neurodegeneration, that kind of clarity may prove to be the most powerful medicine of all.

In an enlightening development, researchers from the Institute of Process Engineering (IPE) at the Chinese Academy of Sciences, in collaboration with the Shenzhen Second People’s Hospital, have formulated an innovative exosome-based therapeutic agent designed specifically for the treatment of traumatic CNS injuries. This groundbreaking approach not only helps alleviate neuronal apoptosis but also restores glial homeostasis and remodels glia-neuron networks, thereby providing substantial therapeutic advantages in murine models of TBI and SCI. Through rigorous experimental studies, the team has successfully outlined the mechanisms by which this therapeutic agent operates, solidifying its potential for future clinical applications.

The impetus behind this research lies in the understanding that neural stem cell (NSC) therapy holds significant promise for CNS repair due to its inherent capacity for promoting cellular regeneration. However, the effectiveness of NSC-based therapies has often been hindered by the pathological microenvironments surrounding the injury sites, which adversely affect NSC survival and their ability to differentiate into mature neurons. This limitation has prompted researchers to explore alternative avenues, particularly focusing on the cellular communicative properties of exosomes. Exosomes are nanosized extracellular vesicles released from various cell types, including NSCs, and possess unique properties that allow them to engage in intercellular signaling within the complex microenvironments of the CNS.

The researchers recognized that the oxidative damage frequently caused by reactive oxygen species (ROS) significantly undermines the therapeutic efficacy of NSC-derived treatments. To address this salient issue, they initiated an innovative approach by encapsulating ultrasmall nano-selenium (Se) within NSC-derived exosomes (referred to as SeNExo). This hybrid agent not only takes advantage of the natural properties of exosomes for efficient cellular communication but also leverages the unique phagocytic properties of nano-selenium to scavenge ROS, thereby creating a dual mechanism for promoting neuronal health and resilience.

Administering SeNExo intravenously to murine models revealed remarkable efficacies in overcoming the blood-brain barrier (BBB)—a formidable challenge in CNS therapeutics. The researchers discovered that upon intravenous injection, SeNExo successfully penetrated the BBB via the APOE_LRP-1 interaction, allowing the therapeutic agents to reach the afflicted areas of the CNS efficiently. Once at the site of injury, the nano-selenium component effectively scavenged ROS, thereby mitigating the oxidative damage, while simultaneously, the NSC-derived exosomes worked to promote neuronal repair and recovery.

Clinical assessments of SeNExo outcomes demonstrated a marked reduction in cerebral lesions in mouse models of TBI, as well as tangible improvements in spatial learning and memory functions. Moreover, through comprehensive proteomics, miRNA omics, and single-nucleus RNA sequencing methodologies, the researchers were able to chart a significant downregulation of genes associated with oxidative stress and neuroinflammation. This paradigm shift not only highlights SeNExo’s multifaceted benefits in injury recovery but also underscores its potential to reshape therapeutic strategies in addressing CNS damage.

The findings advocate for enhanced glial cell resilience and functionality in response to CNS injury. By promoting a shift towards homeostasis among glial cells while enhancing neuron-glia signaling pathways, SeNExo fundamentally alters the transcriptional landscape involved in the inflammatory responses triggered by CNS injuries. The ramifications of this research extend beyond TBI; in SCI models, for instance, the efficacy of SeNExo was similarly pronounced, yielding notable improvements in locomotor recovery.

Prominent figures in the neurological research community, including experts Prof. MA Guanghui from IPE and clinical professionals from Shenzhen Children’s Hospital, have rallied behind the assertion that SeNExo represents a pioneering and promising therapeutic modality for tackling traumatic CNS injuries. Peer reviews from established journals, including the evidence amassed in Cell Reports Medicine, lend credence to the claims surrounding SeNExo’s protective capabilities against TBI and its potential applications for SCI.

Importantly, the overall biocompatibility and stability exhibited by SeNExo provide a compelling argument for its translational potential. Prof. WEI Wei from IPE noted the strong therapeutic efficacy and safety profile highlighted during experimental investigations, positioning SeNExo as a viable candidate for advancing clinically relevant treatments for CNS injuries. Should these findings translate into human applications, the prospects for enhancing recovery among patients suffering from traumatic CNS injuries could witness a substantial transformation.

In essence, the intersection of NSC-derived exosomes and nano-selenium represents an evolution in the approach to CNS injury treatment, paving the way for innovative strategies that may address the limitations of traditional therapies. The multifunctional capabilities of SeNExo underscore the importance of interdisciplinary research in forging new pathways for neuronal regeneration and recovery. As the global medical community increasingly gravitates towards targeted therapies, the implications of these findings serve as a promising beacon of hope for millions of individuals affected by CNS injuries, heralding a new chapter in therapeutic intervention.

The unfolding narrative of SeNExo is one laden with intrigue, as researchers actively explore its full potential in both laboratory conditions and upcoming clinical trials. The future of CNS injury treatments may very well rest upon the effectiveness of agents like SeNExo, igniting hope for a new frontier in medical science. There remains much ground to cover, yet each step forward contributes to our comprehensive understanding of CNS repair mechanisms, fundamentally reshaping how we approach the management of traumatic neurological injuries in years to come.

Subject of Research: Exosome-based therapy for traumatic CNS injuries
Article Title: Innovations in CNS Injury Treatment: The Promise of Exosome-Based Therapies
News Publication Date: August 28, 2025
Web References: http://dx.doi.org/10.1016/j.xcrm.2025.102319
References: Cell Reports Medicine
Image Credits: WANG Wenjing

Keywords

Central nervous system, traumatic brain injury, traumatic spinal cord injury, exosomes, neural stem cells, oxidative stress, nano-selenium, blood-brain barrier, neuroinflammation, therapeutic efficacy, neuronal regeneration, biocompatibility.